

# TIBIAL NERVE STIMULATION: ONE OF SEVERAL NEW OPTIONS FOR THE MANAGEMENT OF OVERACTIVE BLADDER IN WOMEN

---

Scott A Farrell MD

Professor

Dept of Obstetrics and Gynaecology

Dalhousie University

# Declaration of Conflict of Interest

No relationship with pharmaceutical industry

Invented a pessary for SUI


# Objectives

Tibial nerve stimulation- the procedure and evidence

- Mirabegron new  $\beta$ 3 agonist – evidence

Impact on management of Overactive bladder


## Prevalence of Urinary Incontinence Symptoms



# Prevalence of Stress Incontinence by Age Group

Overactive  
bladder

Stress  
Incontinence




## Urgency Incontinence

A loss of urine that is associated with a strong desire to urinate and an inability to delay long enough to get to a toilet.


It usually involves a large amount of urine loss at one time (soaked clothing, running down legs).

It may include urine loss on the way to the bathroom or the "key in the lock" / "hand on the doorknob" syndrome (no urge to urinate until the key is in the doorlock or the hand is on the knob and then it is impossible to wait).



# Neurologic control of the bladder

Cerebral cortex  
micturition center




Pontine  
micturition center

# Causes of Overactive Bladder

- Increased local irritation
  - UTI
  - Lifestyle
  - Stones
- Neurogenic
- Idiopathic



# Cystometry



- Simulate bladder storage
- Standardized filling rate
- Looking for bladder instability
- Ist, full, max cyst cap
- Stimulate at regular intervals

# Unstable bladder on CMG


EMG

PVES


PAbd

PDet

PUre





# Unstable Bladder




# Treatment options for Overactive Bladder

- Identify and treat source of local irritation (UTI)
- Lifestyle modification
- Bladder retraining
- Medications
- Neuromodulation
- Botox

# Origin and Anatomy of Tibial nerve



# Neuromodulation : Tibial Nerve Stimulation



# Neuromodulation : Tibial Nerve Stimulation

- Once per week for 12 weeks
- Session lasts 30 minutes
- Placement of needle is painless
- Stimulation is mild

# Efficacy of Tibial Nerve Stimulation

- Introduced in 2000 at UCSF Medical center
- Multicenter Randomized trial (**OrBIT Trial**)
  - Compared TNS to Detrol LA 4 mg
  - Both groups had significant improvement
  - Subjective improvement –
    - TNS – 80%
    - Detrol – 55%
  - 73% of TNS group who responded continued for 12 months and were able to sustain benefits with treatment every 3 weeks




# Efficacy of Tibial Nerve Stimulation

- Multicenter randomized trial (**SUmiT Trial**)
- Compared TNS to sham
  - 55% of TNS group responded
  - 21% of the sham group
- Effective in women who failed meds
- Cost is significant
  - \$800 for 12 weeks
  - \$66 / session

# Neuromodulation : Tibial Nerve Stimulation

## Global Response Assessment Outcomes after 12 PTNS Treatments for Subjects with UI



*PTNS statistically significant compared to sham for all GRA parameters*

# TNS vs Oxybutinin vs combined therapy

- Randomized prospective study – 12 weeks
- 3 groups
  - Gr I – TNS 30 minutes x2 / week
  - Gr II – Oxybutynin 10mg slow release OD
  - Gr III- combination of above
- Outcomes

Group	OAB score	P value
Group I	5.9	
Group II	4.6	
Group III	2.9	P= 0.01

- At 24 months Gr I and Gr III maintained scores, Gr II went up
- Souto SC World J Urol 2013 Jun 8.

# STEP study of Tibial Nerve Stimulation

- 50 participants of the SUmIT trial who were successfully treated
- 14 week tapering protocol followed by personal treatment plan
  - 2 week intervals – for 2 treatments
  - 3 week intervals- for 2 treatments
  - 4 week interval – for 1 treatment
- Duration 36 months
- Median Treatments 1.1 / month
- 77% maintained moderate or marked improvement
- Peters KM J Urol 2013;189:2194-201.

# Cochrane Review

## Effectiveness of TNS for overactive bladder

Neuro Urodyn 2012;31;1206-1216

- 4 randomized trials compared TNS to sham – significant difference favoured TNS RR 7.02 CI 1.69-29.17
- 2 randomized trials compared TNS to anticholinergics – no difference between therapies
- 10 prospective non-randomized studies
  - Pooled subjective success - 61.4%
  - Pooled objective success – 60.9%



# Cochrane reviews of TNS

- Tirlapur SA - Nerve stimulation for chronic Pelvic pain and bladder pain syndrome
- Acta Obstet Gynecol Scand 2013;92:881-7
  - Controlled studies
  - 169 patients in three studies TNS
  - Improvements in pain, urinary and quality of life scores
- Rai BP -Anticholinergic drugs vs non-drug therapies for non-neurogenic overactive bladder syndrome in adults
- Cochrane Database Syst Rev 2012 Dec 12
  - 23 trials
  - 7 trials compared electrical stim to anticholinergics
  - Only TNS showed significant subjective improvement rates vs anticholinergics

# IWK Experience

- Using TNS for ~ 2 years
- Criteria
  - Pure overactive bladder or minimal stress in mixed incontinence picture
  - Failed trial of at least three anticholinergics
  - Other medical reason to avoid pharmacologic Rx
- Approximately 2/3s respond to treatment
- Clinical trial looking at duration of initial treatment and follow-up protocols

# Neuromodulation: Sacral Nerve Stimulation





# Neuromodulation: Sacral Nerve Stimulation

- \$14,000 per patient
- Invasive procedure
- 30% not eligible
- 30% gain no benefit
- 33% of patients need further operations

# Cost of Neuromodulation Therapies

- Tibial nerve vs sacral nerve stimulation
- Patients who successfully completed initial therapy
  - TNS - \$4,867                      71% remained on therapy
  - SNS – \$24,342                      90% remained on therapy

Martinson M. J Urol 2013; 189:210-16.

# Mirabegron $\beta$ 3 agonist

- B receptors in detrussor muscle
  - **Detrussor relaxation** during filling
  - **Extends the storage phase** of micturition
  - Doesn't affect bladder contraction
- Bioavailability
  - Dependent upon absorption- food intake reduces it
  - Metabolism – genetic influence- CYP2D6
- Anticholinergics
  - **Block detrussor contraction** that initiates voiding
  - **They can interfere** with bladder emptying

# Mirabegron – Blossom trial

- 100 mg and 150 mg BID
- Tolterodine 4mg OD
- Placebo OD
- Inclusion criteria
  - $\geq 3$  episodes of severe urgency / day
  - $> 8$  voids in 24 hours
- Primary outcome – change in mean number of micturitions in 24 hrs
- Mean decrease 1 mic / 24 hrs
- Mean reduction – 17%, 18%, 11% and 9%

# Mirabegron – Dragon trial

- 1110 patients randomized 12 weeks (919 analyzed)
- Dosages – 25,50,100 and 200 OD
- Tolterodine 4mg OD
- Placebo OD
- Outcome
  - Significant dose dependent reduction of mean number of micturitions/ 24hrs
    - Mirabegron – 1.9 -2.2
    - Placebo – 1.4
  - Increase in mean voided volume
    - Mirebegron - 15.7 – 33.3 ml
    - Placebo – 7.3 ml

# Mirabegron – Subsequent Clinical trials

- 2 randomized placebo controlled trials
- Inclusion -  $\geq 8$  voids in 24 hrs ,  $\geq 3$  urgency episodes / day
- Study 1 – mirabegron – 50mg, 100mg vs placebo
  - Reduction in mean # of incontinence episodes -1.5, -1.6 , -1.1
  - Reduction in # of micturitions /24hrs -1.7,-1.8, -1.1
  - Number of patients with no incontinence was not reported
- Study 2 – mirabegron 50mg, 100mg, Tolter 4mg, placebo
  - Reduction in mean # of incontinence episodes -1.5, -1.6 , -1.2, -1.1
  - Reduction in # of micturitions/24hrs -1.8,-1.9, -1.6 -1.3
  - The difference in responders ( dry after Rxment)
    - Mirabegron – 45%
    - Placebo – 41% (p= 0.26)
  - Improvements in quality of life in all active treatment groups

# Mirabegron – 12 month Safety Study

- Mirabegron 50mg, 100mg
- Tolteridine – 4 mg
- Incidence and severity of treatment related side-effects
- Results
  - No difference in patients D/C because of side effects 5.9-6.4%
  - More dry mouth in the tolteridine group

# Assessment of clinical trial data

- Follow-up very short
- No study done to compare mirabegron to anti-muscarinic
- Urgency – key symptom of OAB was secondary end-point
- High placebo response calls into question efficacy of mirabegron vs nothing, in clinical practice – absolute improvement small:
  - One less incontinence episode and micturition every 2 days with mirabegron
- Exclusions
  - End stage renal disease
  - Severe hepatic impairment
  - Uncontrolled hypertension





# Side –effects of Mirabegron

- Appears to be well tolerated
- Commonest side-effects
  - Tachycardia – 1.2%
  - UTI's – 2.9%
  - Serious adverse events – atrial fibrillation – 0.2%
- Important identified risks
  - Increased heart rate
  - Tachycardia
- Important potential risks
  - QT prolongation
  - Hypertension
  - UTI
- Drug interactions – some anti-arrhythmics, tricyclic ad

# Mirabegron

- Conclusions
  - Clinical effectiveness similar to antimuscarinics
  - Different side-effect profile – less dry mouth
  - Differences in costs and effectiveness small
- Recommendations (NICE)
  - Anti-muscarinic drugs should be first choice
  - Use Mirabegron when Anti-muscarinics
    - are contraindicated (glaucoma)
    - Clinically ineffective
    - Have unacceptable side-effects
  - May be preferable in elderly patients because of
    - Greater aversion to dry mouth
    - Less likely to cause cognitive dysfunction

# Botox Injections



# Botox Injections

- General or local anaesthetic – 10-30 minutes
- 10-30 injection sites
- May need to self-cath after procedure
- Lasts 3-6 months

# How does this information affect our management of OAB ?

- Effective treatment options
  - Lifestyle modification
  - Anticholinergics
  - B3 agonist
  - Tibial nerve stimulation
  - Sacral nerve stimulation
  - Botox injections
- How do we choose and in what order?
- Factors to consider
  - Efficacy
  - Safety
  - Cost
  - Convenience
  - Patient preference

# Convenience

- Lifestyle modification can be done in your own home
- Drugs, once purchased last for a month
- Tibial nerve stim requires frequent visits to hospital or other facility
- Sacral nerve stim and botox are surgical procedures and most likely will require frequent follow-up

# Efficacy

- Lifestyle modification can be very effective
- Pharmacologic options – no clearly superior option
- Neuromodulation is as effective as pharmacologic treatment
- Botox – effective but no comparison trials

# Safety

- Lifestyle modification- safest option, no contraindications
- Tibial nerve stimulation – no complications, no side-effects, no contraindications
- Pharmacotherapy – low rate of significant complications, significant side-effects result in low long-term compliance rate, all have contraindications
- Sacral neuromodulation – invasive, low rate of severe complications
- Botox – invasive, low rate of severe complications



# Cost

- Lifestyle modification usually saves money
- Pharmacotherapy is expensive \$85- \$100/month (Usually covered by insurance)
- Tibial nerve stimulation – initial therapy expensive ~\$800 for 12 treatments but maintenance could be as low as \$66/month( not covered by insurance)
- Sacral nerve stimulation very expensive up front cost ~\$14,000 and high rate of malfunction with on-going costs
- Botox - \$2-3000 with repeat treatment every 3-4 months

# Patient Preference

- Lifestyle modification – nobody likes it
- Pharmacotherapy – high none compliance
- Tibial nerve – well tolerated but inconvenient
- Sacral nerve stim – invasive and inconvenient
- Botox – invasive but well tolerated

# Conclusions

- Options for treating overactive bladder are expanding
- Choice of therapy will be influenced by a number of patient factors
- Algorithm
  - Lifestyle
  - Bladder drill
  - Tibial nerve stim
  - Pharmacotherapy
    - Anticholinergics followed by  $\beta$ 3 agonist
  - Sacral nerve stim and botox for resistant cases

# QUESTIONS AND COMMENTS

---

# Investigations of Urinary Incontinence

- Urine C&S
- QUID questionnaire
- Urolog

# URINE C&S

---

# QUID Questionnaire

Please complete all questions. Do not leave any questions blank. For each question, mark the box that most accurately describes how often you experience your symptoms.

Do you leak urine (even small drops), wet yourself, or wet your pads or undergarments...						
	None of the time	Rarely	Once in a while	Often	Most of the time	All of the time
1. When you cough, laugh or sneeze?						
2. When you bend down or lift something up?						
3. When you walk quickly, jog, or exercise?						
Do you leak urine (even small drops), wet yourself, or wet your pads or undergarments...						
4. While you are undressing to use the toilet?						
5. Do you get such a strong and uncomfortable need to urinate that you leak urine (even small drops) or wet yourself before reaching the toilet?						
6. Do you have to rush to the bathroom because you get a sudden, strong need to urinate?						

Assessment of Incontinence Type


A score on the first three questions (#1, 2, 3) of  $\geq 4$  correlates with **stress incontinence**.

A score on the last three questions (#4, 5, 6) of  $\geq 6$  correlates with **urge incontinence or urgency incontinence**.





# How to triage and Direct Your Patient



# What the Family Doctor Can do

- ⊙ Identify and treat UTI
- ⊙ Direct patient to reliable information  
[www.womensbladderhealth.com](http://www.womensbladderhealth.com)
- ⊙ Advise patient on lifestyle changes
- ⊙ Advise on Kegels exercises – refer to physio

# Stress incontinence

## Urogynaecologist

- Pessaries
- Midurethral slings
- Retropubic slings
- Burch procedure
- Periurethral bulking

## Urologist

- Midurethral slings
- Retropubic slings

# Urge Incontinence

## Urogynaecologist


- Full evaluation using urodynamics
- Anticholinergics
- Tibial nerve stimulation

## Urologist

- Full evaluation using urodynamics
- Anticholinergics
- Sacral nerve stimulation
- Botox?
- Bladder augmentation

Stress Incontinence - failure of the urethra, the "valve" which closes the bladder.

The involuntary loss of small amounts of urine in response to increased pressure on the bladder (for example, when a person coughs, sneezes, laughs, or lifts heavy objects urine leaks out).



# Indications for Cystometry

- Assess bladder capacity
  - 1st sensation – 100 -200 ml
  - Volume at normal desire to void – 150 – 350 ml
  - Maximum cystometric capacity - 300 -600 ml
- Bladder compliance
  - Increase of no more than 15 cm of H<sub>2</sub>O
- Detrusor stability

QUESTIONS AND  
COMMENTS?

---